Merck MRK announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by the end of 2027.

Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...